OS Therapies' (OSTX) Buy Rating Reiterated at D. Boral Capital

Key Points

• D. Boral Capital reaffirmed a buy rating on OS Therapies with a $20.00 price objective.
• The stock rose about 4.5% to $1.43 on Friday; the company has a market capitalization near $50.4 million, a negative PE (−1.75), and a 12‑month range of $1.12–$2.57.
• Several institutional investors (including Two Sigma and CM Management) recently bought or increased stakes, while OS Therapies remains a clinical‑stage biopharma developing OST‑HER2 and OST‑tADC therapies for osteosarcoma and other solid tumors.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at D. Boral Capital in a research note issued to investors on Friday,Benzinga reports. They currently have a $20.00 price objective on the stock.

OS Therapies Stock Up 4.5%

Shares of NYSEAMERICAN:OSTX traded up $0.06 during trading on Friday, hitting $1.43. The stock had a trading volume of 481,348 shares, compared to its average volume of 576,358. The company has a market capitalization of $50.39 million, a PE ratio of -1.75 and a beta of -3.80. The firm's fifty day moving average is $1.40 and its 200 day moving average is $1.68. OS Therapies has a 12 month low of $1.12 and a 12 month high of $2.57.

Institutional Trading of OS Therapies

Several large investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in OS Therapies during the second quarter valued at about $63,000. Bridgeway Capital Management LLC bought a new position in shares of OS Therapies in the second quarter worth about $47,000. Ground Swell Capital LLC bought a new position in shares of OS Therapies in the third quarter worth about $40,000. CM Management LLC grew its position in shares of OS Therapies by 6.7% during the third quarter. CM Management LLC now owns 400,000 shares of the company's stock worth $784,000 after purchasing an additional 25,000 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of OS Therapies during the third quarter worth about $169,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.